{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:52Z","timestamp":1784052232881,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372910"],"award-info":[{"award-number":["82372910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24SF1904600"],"award-info":[{"award-number":["24SF1904600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","award":["201840209"],"award-info":[{"award-number":["201840209"]}],"id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05212-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:44:56Z","timestamp":1779360296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Institutional experience and pooled survival analysis of chemotherapy based multimodal management in poorly differentiated chordoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Jingyu","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlan","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"2","key":"5212_CR1","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","volume":"13","author":"BP Walcott","year":"2012","unstructured":"Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69\u201376.","journal-title":"Lancet Oncol"},{"issue":"5","key":"5212_CR2","doi-asserted-by":"publisher","first-page":"188796","DOI":"10.1016\/j.bbcan.2022.188796","volume":"1877","author":"EN Karele","year":"2022","unstructured":"Karele EN, Paze AN, Chordoma: to know means to recognize. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188796.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"5212_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/apm.12978","volume":"127","author":"HG Yeter","year":"2019","unstructured":"Yeter HG, Kosemehmetoglu K, Soylemezoglu F. Poorly differentiated chordoma: review of 53 cases. APMIS. 2019;127(9):607\u201315.","journal-title":"APMIS"},{"issue":"6","key":"5212_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00401-010-0767-x","volume":"120","author":"BC Mobley","year":"2010","unstructured":"Mobley BC, Mckenney JK, Bangs CD, et al. Loss of SMARCB1\/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120(6):745\u201353.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"5212_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/his.14056","volume":"76","author":"P Balogh","year":"2020","unstructured":"Balogh P, O\u2019donnell P, Lindsay D, et al. Extra-axial skeletal poorly differentiated chordoma: a case report. Histopathology. 2020;76(6):924\u20137.","journal-title":"Histopathology"},{"issue":"1","key":"5212_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/neup.12407","volume":"38","author":"YJ Cha","year":"2018","unstructured":"Cha YJ, Hong CK, Kim DS, et al. Poorly differentiated chordoma with loss of SMARCB1\/INI1 expression in pediatric patients: a report of two cases and review of the literature. Neuropathology. 2018;38(1):47\u201353.","journal-title":"Neuropathology"},{"issue":"1","key":"5212_CR7","first-page":"33","volume":"51","author":"ZJ Duan","year":"2022","unstructured":"Duan ZJ, Yao K, Ma Z, et al. [Pediatric SMARCB1\/INI1-deficient poorly differentiated chordoma of the skull base: report of five cases and review of literature]. Zhonghua Bing Li Xue Za Zhi. 2022;51(1):33\u20138.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"5212_CR8","doi-asserted-by":"crossref","unstructured":"John L, Smith H, Ilanchezhian M, et al. The NIH pediatric\/young adult chordoma clinic and natural history study: Making advances in a very rare tumor. Pediatr Blood Cancer. 2023: e30358.","DOI":"10.1002\/pbc.30358"},{"issue":"11","key":"5212_CR9","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.3390\/ijms25115877","volume":"25","author":"R Desai","year":"2024","unstructured":"Desai R, Pelargos PE, Dunn IF, Chordoma: genetics and Contemporary Management. Int J Mol Sci. 2024;25(11):5877.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5212_CR10","doi-asserted-by":"publisher","first-page":"e2141927","DOI":"10.1001\/jamanetworkopen.2021.41927","volume":"5","author":"YU Yolcu","year":"2022","unstructured":"Yolcu YU, Zreik J, Wahood W, et al. Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma. JAMA Netw Open. 2022;5(1):e2141927.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"5212_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/neuonc\/nou331","volume":"17","author":"T Meng","year":"2015","unstructured":"Meng T, Yin H, Li B, et al. Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center. Neuro Oncol. 2015;17(5):725\u201332.","journal-title":"Neuro Oncol"},{"key":"5212_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejca.2017.06.038","volume":"83","author":"V Colia","year":"2017","unstructured":"Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer. 2017;83:220\u20138.","journal-title":"Eur J Cancer"},{"issue":"2","key":"5212_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/pbc.23297","volume":"59","author":"MM Al-Rahawan","year":"2012","unstructured":"Al-Rahawan MM, Siebert JD, Mitchell CS, et al. Durable complete response to chemotherapy in an infant with a clival chordoma. Pediatr Blood Cancer. 2012;59(2):323\u20135.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"5212_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2025.0017","volume":"23","author":"JS Biermann","year":"2025","unstructured":"Biermann JS, Hirbe A, Ahlawat S, et al. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(4):1.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"5212_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","volume":"32","author":"SJ Strauss","year":"2021","unstructured":"Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520\u201336.","journal-title":"Ann Oncol"},{"issue":"9","key":"5212_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/S1470-2045(20)30466-6","volume":"21","author":"C Liu","year":"2020","unstructured":"Liu C, Jia Q, Wei H, et al. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2020;21(9):1244\u201352.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5212_CR17","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.currproblcancer.2021.100771","volume":"45","author":"MF Wedekind","year":"2021","unstructured":"Wedekind MF, Widemann BC, Cote G. Chordoma: Current status, problems, and future directions. Curr Probl Cancer. 2021;45(4):100771.","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"5212_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41379-018-0002-1","volume":"31","author":"AR Shih","year":"2018","unstructured":"Shih AR, Cote GM, Chebib I, et al. Clinicopathologic characteristics of poorly differentiated chordoma. Mod Pathol. 2018;31(8):1237\u201345.","journal-title":"Mod Pathol"},{"issue":"6","key":"5212_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.6004\/jnccn.2013.0089","volume":"11","author":"BJ Williams","year":"2013","unstructured":"Williams BJ, Raper DM, Godbout E, et al. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw. 2013;11(6):726\u201331.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"5212_CR20","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.modpat.2024.100664","volume":"38","author":"WJ Sande","year":"2025","unstructured":"Sande WJ, Folpe AL, O\u2019connor P, et al. Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization. Mod Pathol. 2025;38(3):100664.","journal-title":"Mod Pathol"},{"issue":"12","key":"5212_CR21","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1007\/s00381-024-06641-z","volume":"40","author":"A Goyal","year":"2024","unstructured":"Goyal A, Shah K, Uppar AM, et al. Poorly differentiated chordoma: recognising this complex and rare aggressive tumour with characteristic immunohistochemical profile. Childs Nerv Syst. 2024;40(12):4309\u201314.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"5212_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00401-016-1574-9","volume":"132","author":"M Hasselblatt","year":"2016","unstructured":"Hasselblatt M, Thomas C, Hovestadt V, et al. Poorly differentiated chordoma with SMARCB1\/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol. 2016;132(1):149\u201351.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"5212_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/gcc.22895","volume":"60","author":"C Curcio","year":"2021","unstructured":"Curcio C, Cimera R, Aryeequaye R, et al. Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report. Genes Chromosomes Cancer. 2021;60(1):43\u20138.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"5212_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/gcc.22992","volume":"60","author":"X Wen","year":"2021","unstructured":"Wen X, Cimera R, Aryeequaye R, et al. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis. Genes Chromosomes Cancer. 2021;60(12):796\u2013807.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"5212_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAS.0000000000000741","volume":"41","author":"M Antonelli","year":"2017","unstructured":"Antonelli M, Raso A, Mascelli S, et al. SMARCB1\/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis. Am J Surg Pathol. 2017;41(1):56\u201361.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5212_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/10668969241286086","volume":"33","author":"P O\u2019Connor","year":"2025","unstructured":"O\u2019Connor P, Cheung YY, Green DC, et al. Extra-Axial Poorly Differentiated Chordoma Initially Misdiagnosed as Epithelioid Sarcoma. Int J Surg Pathol. 2025;33(3):646\u201355.","journal-title":"Int J Surg Pathol"},{"key":"5212_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2021.03.001","volume":"112","author":"K Kohashi","year":"2021","unstructured":"Kohashi K, Yamamoto H, Yamada Y, et al. Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid\/rhabdoid tumor. Hum Pathol. 2021;112:1\u20138.","journal-title":"Hum Pathol"},{"issue":"2","key":"5212_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/PAI.0000000000000554","volume":"27","author":"AM Buccoliero","year":"2019","unstructured":"Buccoliero AM, Caporalini C, Scagnet M, et al. A Diagnostic Pitfall: Atypical Teratoid Rhabdoid Tumor Versus Dedifferentiated\/Poorly Differentiated Chordoma: Analysis of a Mono-institutional Series. Appl Immunohistochem Mol Morphol. 2019;27(2):147\u201354.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"5212_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/path.6135","volume":"260","author":"S Haefliger","year":"2023","unstructured":"Haefliger S, Chervova O, Davies C, et al. Subclassification of epithelioid sarcoma with potential therapeutic impact. J Pathol. 2023;260(4):368\u201375.","journal-title":"J Pathol"},{"issue":"1","key":"5212_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-024-04841-w","volume":"171","author":"M De Robertis","year":"2025","unstructured":"De Robertis M, Ghermandi R, Pipola V, et al. Therapeutic strategies for mobile spine chordoma: en bloc Versus intralesional surgery with adjuvant charged-particle therapy. J Neurooncol. 2025;171(1):229\u201340.","journal-title":"J Neurooncol"},{"issue":"12","key":"5212_CR31","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s12094-022-02915-7","volume":"24","author":"Y Wang","year":"2022","unstructured":"Wang Y, Peng Z, Wang Y, et al. The prognostic significance of different degrees of resection of skull base chordoma. Clin Transl Oncol. 2022;24(12):2441\u201352.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"5212_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijrobp.2025.03.075","volume":"123","author":"M Ioakeim-Ioannidou","year":"2025","unstructured":"Ioakeim-Ioannidou M, Niemierko A, Mukhammadov T, et al. Long-term Outcomes Following Proton-based Radiation Therapy for Pediatric Chordomas and Chondrosarcomas of the Mobile Spine and the Sacrum. Int J Radiat Oncol Biol Phys. 2025;123(1):63\u201373.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"5212_CR33","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/neuonc\/noad068","volume":"25","author":"M Ioakeim-Ioannidou","year":"2023","unstructured":"Ioakeim-Ioannidou M, Niemierko A, Kim DW, et al. Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. Neuro Oncol. 2023;25(9):1686\u201397.","journal-title":"Neuro Oncol"},{"issue":"1","key":"5212_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-009-0068-1","volume":"98","author":"BJ Jian","year":"2010","unstructured":"Jian BJ, Bloch OG, Yang I, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol. 2010;98(1):101\u20138.","journal-title":"J Neurooncol"},{"issue":"2","key":"5212_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/sc.2009.95","volume":"48","author":"KW Chen","year":"2010","unstructured":"Chen KW, Yang HL, Lu J, et al. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2010;48(2):166\u201371.","journal-title":"Spinal Cord"},{"key":"5212_CR36","doi-asserted-by":"publisher","first-page":"686565","DOI":"10.3389\/fonc.2021.686565","volume":"11","author":"FS Liu","year":"2021","unstructured":"Liu FS, Zheng BW, Zhang TL, et al. Clinicopathological and Prognostic Characteristics in Dedifferentiated\/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data from 58 Studies and Comparison With Conventional Chordomas. Front Oncol. 2021;11:686565.","journal-title":"Front Oncol"},{"issue":"7","key":"5212_CR37","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1158\/1078-0432.CCR-18-3133","volume":"25","author":"MM Gounder","year":"2019","unstructured":"Gounder MM, Zhu G, Roshal L, et al. Immunologic Correlates of the Abscopal Effect in a SMARCB1\/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy. Clin Cancer Res. 2019;25(7):2064\u201371.","journal-title":"Clin Cancer Res"},{"key":"5212_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fonc.2019.00030","volume":"9","author":"T Meng","year":"2019","unstructured":"Meng T, Jin J, Jiang C, et al. Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review. Front Oncol. 2019;9:30.","journal-title":"Front Oncol"},{"issue":"1","key":"5212_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41698-021-00238-4","volume":"5","author":"LM Williamson","year":"2021","unstructured":"Williamson LM, Rive CM, Di Francesco D, et al. Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. NPJ Precis Oncol. 2021;5(1):103.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"5212_CR40","doi-asserted-by":"publisher","first-page":"E1095","DOI":"10.1093\/neuros\/nyz333","volume":"85","author":"MX Zou","year":"2019","unstructured":"Zou MX, Zheng BW, Liu FS, et al. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Neurosurgery. 2019;85(6):E1095\u2013110.","journal-title":"Neurosurgery"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05212-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05212-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05212-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:05:12Z","timestamp":1784048712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05212-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5212"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05212-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by the Ethics Committee of The Shanghai Changzheng Hospital. And the research complies with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all adult patients. For patients under the age of 18, written informed consent was obtained from their parents or legal guardians, and assent was obtained from the minor patients.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients have consented to publish their medical information.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research project was examined and approved by the medical ethics committee of Shanghai Changzheng Hospital.","order":4,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients or their legal guardians..","order":5,"name":"Ethics","label":"Informed consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1022"}}